• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

成纤维细胞生长因子受体 2：胃癌治疗靶点。

Fibroblast growth factor receptor 2: a therapeutic target in gastric cancer.

机构信息

State Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi Province, China.

出版信息

Expert Rev Gastroenterol Hepatol. 2013 Nov;7(8):759-65. doi: 10.1586/17474124.2013.837804. Epub 2013 Oct 17.

DOI:10.1586/17474124.2013.837804
PMID:24134151
Abstract

Gastric cancer remains a leading cause of cancer-related death in the world. FGF receptor 2 (FGFR2) is preferentially amplified and overexpressed in the diffuse type of gastric cancer. This review evaluates the expression and function of FGFR2 in gastric cancer, and analyzes the use of its inhibitors for gastric cancer therapy. This review also discusses the limitations of FGFR2-based therapy, and envisages future developments toward the clinical applications of FGFR2.

摘要

胃癌仍然是全球癌症相关死亡的主要原因。成纤维细胞生长因子受体 2（FGFR2）在弥漫型胃癌中优先扩增和过表达。本综述评估了 FGFR2 在胃癌中的表达和功能，并分析了其抑制剂在胃癌治疗中的应用。本综述还讨论了基于 FGFR2 治疗的局限性，并展望了 FGFR2 临床应用的未来发展。

相似文献

1
Fibroblast growth factor receptor 2: a therapeutic target in gastric cancer.成纤维细胞生长因子受体 2：胃癌治疗靶点。
Expert Rev Gastroenterol Hepatol. 2013 Nov;7(8):759-65. doi: 10.1586/17474124.2013.837804. Epub 2013 Oct 17.
2
Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors.沙卡替尼抑制对间质表皮转化因子和成纤维细胞生长因子受体抑制剂耐药的弥漫型胃癌细胞的腹膜扩散。
Cancer Sci. 2014 May;105(5):528-36. doi: 10.1111/cas.12387. Epub 2014 Mar 24.
3
FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.FGFR2扩增的胃癌细胞系生长和存活需要FGFR2和Erbb3信号传导。
Cancer Res. 2008 Apr 1;68(7):2340-8. doi: 10.1158/0008-5472.CAN-07-5229.
4
Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells.上皮-间质转化赋予SNU-16胃癌细胞对选择性FGFR抑制剂的抗性。
Gastric Cancer. 2016 Jan;19(1):53-62. doi: 10.1007/s10120-014-0444-1. Epub 2014 Nov 19.
5
Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.在 HER2 阳性乳腺癌细胞中 HER2 和 FGFR2 之间的成瘾性切换：拉帕替尼失败后的挽救治疗靶点 FGFR2。
Biochem Biophys Res Commun. 2011 Apr 1;407(1):219-24. doi: 10.1016/j.bbrc.2011.03.002. Epub 2011 Mar 4.
6
AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.AZD2171对过表达成纤维细胞生长因子受体2/角质形成细胞生长因子受体的胃癌显示出强大的抗肿瘤活性。
Clin Cancer Res. 2007 May 15;13(10):3051-7. doi: 10.1158/1078-0432.CCR-06-2743.
7
Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.多种受体酪氨酸激酶激活减弱了成纤维细胞生长因子受体2抑制剂AZD4547在FGFR2扩增胃癌中的治疗效果。
Oncotarget. 2015 Feb 10;6(4):2009-22. doi: 10.18632/oncotarget.2987.
8
Is FGFR2 a Suitable Target to Treat Scirrhous-Type Gastric Cancer?
Ann Surg Oncol. 2019 Apr;26(4):926-927. doi: 10.1245/s10434-018-07146-1. Epub 2019 Jan 8.
9
Targeted therapy for gastric cancer--current status.胃癌的靶向治疗——现状
J Oncol Pharm Pract. 2013 Mar;19(1):75-81. doi: 10.1177/1078155212449030. Epub 2012 Jun 18.
10
RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance.RNA 干扰筛选鉴定出自分泌成纤维细胞生长因子信号在神经母细胞瘤化疗耐药中的新作用。
Oncogene. 2013 Aug 22;32(34):3944-53. doi: 10.1038/onc.2012.416. Epub 2012 Oct 1.

引用本文的文献

1
SHP2 as a Potential Therapeutic Target in Diffuse-Type Gastric Carcinoma Addicted to Receptor Tyrosine Kinase Signaling.SHP2作为弥漫型胃癌中依赖受体酪氨酸激酶信号传导的潜在治疗靶点
Cancers (Basel). 2021 Aug 26;13(17):4309. doi: 10.3390/cancers13174309.
2
2b or Not 2b: How Opposing FGF Receptor Splice Variants Are Blocking Progress in Precision Oncology.2b还是非2b：相反的成纤维细胞生长因子受体剪接变体如何阻碍精准肿瘤学的进展
J Oncol. 2021 Apr 30;2021:9955456. doi: 10.1155/2021/9955456. eCollection 2021.
3
The association of genetic variants in with osteoporosis susceptibility in Chinese Han population.
基因变异与中国汉族人群骨质疏松易感性的关联。
Biosci Rep. 2019 Jun 4;39(6). doi: 10.1042/BSR20190275. Print 2019 Jun 28.
4
Bone remodeling induced by mechanical forces is regulated by miRNAs.机械力诱导的骨重建受 miRNAs 调控。
Biosci Rep. 2018 Jul 2;38(4). doi: 10.1042/BSR20180448. Print 2018 Aug 31.
5
MicroRNA-195 inhibits human gastric cancer by directly targeting basic fibroblast growth factor.MicroRNA-195 通过直接靶向碱性成纤维细胞生长因子抑制人胃癌。
Clin Transl Oncol. 2017 Nov;19(11):1320-1328. doi: 10.1007/s12094-017-1668-4. Epub 2017 May 12.
6
FGF7/FGFR2 signal promotes invasion and migration in human gastric cancer through upregulation of thrombospondin-1.FGF7/FGFR2信号通过上调血小板反应蛋白-1促进人胃癌的侵袭和迁移。
Int J Oncol. 2017 May;50(5):1501-1512. doi: 10.3892/ijo.2017.3927. Epub 2017 Mar 22.
7
Identification of novel peptoid agonists of fibroblast growth factor receptor using microarray-based screening.使用基于微阵列的筛选方法鉴定成纤维细胞生长因子受体的新型拟肽激动剂。
Medchemcomm. 2016;7:1183-1189. doi: 10.1039/C6MD00121A. Epub 2016 Apr 14.
8
The anti-apoptotic and prognostic value of fibroblast growth factor 9 in gastric cancer.成纤维细胞生长因子9在胃癌中的抗凋亡及预后价值
Oncotarget. 2016 Jun 14;7(24):36655-36665. doi: 10.18632/oncotarget.9131.
9
Patient-Derived Gastric Carcinoma Xenograft Mouse Models Faithfully Represent Human Tumor Molecular Diversity.患者来源的胃癌异种移植小鼠模型忠实地反映了人类肿瘤的分子多样性。
PLoS One. 2015 Jul 28;10(7):e0134493. doi: 10.1371/journal.pone.0134493. eCollection 2015.
10
Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets.用于药物靶向细胞内递送的模块化纳米转运体：叶酸受体作为潜在靶点。
Curr Pharm Des. 2015;21(9):1227-38. doi: 10.2174/1381612820666141013121032.